Log In
BCIQ
Print this Print this
 

Apriso, granulated mesalamine

  Manage Alerts
Collapse Summary General Information
Company Dr. Falk Pharma GmbH
DescriptionMesalamine delivered to the distal ileum and colon via dual-release granules
Molecular Target Not available
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationInflammatory bowel disease (IBD)
Indication DetailsMaintain remission of ulcerative colitis (UC)
Regulatory Designation
PartnerValeant Pharmaceuticals International Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$12,524.0M

$11,689.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

04/01/2015

$11,400.0M

$11,400.0M

0

03/11/2015

$1,124.0M

$289.0M

0

Get a free BioCentury trial today